As a new-type foreign trade service provider driven by both technology transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory sources of Tris(dibenzylideneacetone)dipalladium chloroform adduct from multiple well-known brands.
With R&D capabilities, HiSiaddi has repeatedly proposed formula optimization schemes and application improvement suggestions for Tris(dibenzylideneacetone)dipalladium chloroform adduct through technological transformation cooperation with manufacturers and accurate market insight. Below is a consulting case of HiSiaddi’s formula optimization for this product.
For more formula optimization consulting services, please contact HiSiaddi customer service.
Novapharma SAS, a Lyon-based French high-end innovative drug API enterprise, specializes in industrial mass production of neural targeted drug intermediates and clinical new drug development. Tris(dibenzylideneacetone)dipalladium chloroform adduct (Pd₂(dba)₃·CHCl₃, CAS 52522-40-4) acts as the core zero-valent palladium catalyst for Buchwald-Hartwig arylamination reactions, with an annual procurement demand of 145 kg and long-term reliance on pharmacopoeia-grade imported raw materials from Johnson Matthey.
Amid surging European precious metal prices and extended import lead times of up to 65 days, the client piloted localized procurement by selecting standard pharmaceutical-grade products from a domestic manufacturer. After the first 60 kg of raw material was launched on the continuous mass production line, multiple production failures occurred consecutively: the yield of the main API product plummeted from 94.8% (original imported material) to 81%–85%, byproduct impurities surged, large amounts of black palladium black precipitate accumulated at the reactor bottom, and catalytic activity varied by over 10% before and after feeding from the same batch of catalyst, forcing intermittent line shutdowns for adjustments.
Bound by French pharmaceutical regulatory registration requirements, the entire coupling reaction temperature, solvent ratio, and base dosage were locked in filed registration documents and could not be altered on-site. Troubleshooting was limited to two directions: modification of the catalyst’s own formula and optimization of on-site feeding procedures. The original supplier only possessed mass production synthesis capacity with fixed mass production formulas and lacked familiarity with downstream arylamination working conditions, making it unable to adjust product formulas to resolve the client’s production failures. The client urgently entrusted HiSiaddi to lead full-process fault tracing, iterative formula optimization, and on-site application guidance delivery.
HiSiaddi collected failed domestic catalyst from the client, original Johnson Matthey reference samples, and unopened warehouse retained samples, conducting full physical and chemical testing alongside a precious metal catalysis laboratory. We simultaneously coordinated remote communication with the client’s workshop process engineers to sort out full-process details of feeding, warehousing and reactions, precisely pinpointing the root causes of failures:
Conventional domestic formulas feature 12% excess dibenzylideneacetone (DBA) feeding, resulting in finished free DBA residues of 1150 ppm (vs. ≤220 ppm for imported raw materials). Crude temperature control during crystallization leads to 820 ppm free chloroform encapsulated in crystal lattices. Excess free DBA undergoes self-condensation in alkaline coupling systems to generate impurities; heated decomposition of free chloroform releases trace chloride ions, disrupting the zero-valent palladium coordination structure and triggering in-situ catalyst decomposition to precipitate inactive elemental palladium black, which adsorbs target products and drastically reduces main product yields.
No inert antioxidant stabilizer additives are incorporated into manufacturers’ standard formulas. During storage in ambient-temperature French warehouses, chloroform gradually detaches from crystal lattices, and zero-valent palladium oxidizes and agglomerates upon exposure to trace water vapor. The client uses large 25 kg drums opened in full for partial batch feeding; residual material stored for 4–6 days after opening exhibits significant catalytic activity decay, leading to activity divergence within the same batch.
Natural ambient-temperature crystallization yields particle sizes spanning 5 μm to 55 μm: ultrafine powder instantly deactivates upon contact with solvent, while large particles require extended dissolution time. The client followed feeding protocols for imported catalysts by directly adding dry powder to high-temperature reactors, creating localized high palladium concentrations that trigger palladium atomic agglomeration and deactivation, further exacerbating activity fluctuations and palladium black generation.
1. Precise optimization of coordination feeding formula: Fix the molar ratio of palladium source to DBA at 2:3.02, abandoning the original excess feeding ratio. Alkali solution is added dropwise in staged batches under closed inert nitrogen protection with strict pH control of the system to minimize uncoordinated free DBA generation from the source. Optimize chloroform recrystallization feeding volume to guarantee exactly one chloroform molecule embedded in each crystal lattice unit, limiting free chloroform to ≤380 ppm and free DBA residues to 160–200 ppm, fundamentally eliminating triggers for side reactions.
2. Addition of trace inert stabilizers to formulas to boost storage stability: A 50 ppm inert ketone stabilizer is added to finished formulas without interfering with catalytic activity, paired with low-temperature negative-pressure staged drying to inhibit chloroform decomplexation and palladium oxidation during storage. Activity decay after 6 months of sealed ambient storage is controlled below 3%, resolving rapid degradation after package opening.
3. Directional crystal control for optimized particle size formulas: Adopt gradient uniform cooling crystallization (0.7 °C/h cooling rate) with trace crystal regulation additives to narrow the particle size distribution to D50=20–28 μm. Uniform dissolution rates in reaction solvents eliminate activity differences caused by inconsistent dissolution times of coarse and fine particles. HiSiaddi sent three rounds of lab trial samples to the French laboratory and fine-tuned formula details based on small-batch yield data before finalizing the mass production formula.
1. Optimize feeding pre-treatment procedures: Abandon direct dry powder feeding. Pre-disperse the catalyst in anhydrous deoxygenated toluene under sealed low-temperature conditions (10–15 °C) with stirring for 30 minutes; filter out surface dampened, oxidized and deactivated powder before transferring to the reactor to avoid deteriorated material entering the vessel and generating palladium black.
2. Split packaging + optimize warehousing specifications: Advise the client to replace 25 kg large drums with independent 1 kg vacuum aluminum foil small pouches for single-opening immediate use. Adjust raw material storage to constant temperature 2–8 °C light-shielded refrigeration to isolate air and water vapor, eliminating moisture-induced deterioration from long-term open storage of full drums.
3. Fine-tune feeding rhythm (without altering original reaction ratio and temperature): Replace one-time full feeding with two split additions separated by a 35-minute interval after heating to the specified process temperature, lowering instantaneous palladium concentration and reducing risks of localized agglomeration and deactivation.
1. Pilot production of optimized grade: The manufacturer produced 55 kg of improved product per the revised formula, accompanied by Chinese-English bilingual COA compliant with French pharmacopoeia and REACH-compliant SDS. Upon arrival at the Lyon plant, full-line pilot testing of the material delivered stable arylamination main product yields of 93.9%–94.7%, matching original imported material performance. Total byproducts decreased by 68%, palladium black generation at reactor bottoms was nearly eliminated, and batch activity fluctuations were controlled within ±1.5%, restoring full-load production capacity of the line.
2. Execution of annual 145 kg procurement contract: The client terminated import procurement from Johnson Matthey, with annual shipments scheduled monthly across seven batches. HiSiaddi arranged third-party full re-inspection before factory release for every batch to lock consistent indicators. Localized procurement costs decreased by 30.2% relative to original imported materials, and sea freight lead times were cut from 65 days to 21 days.
3. Business expansion: In the following year, the client launched pilot R&D of a new generation of anti-depressant drugs requiring a modified low-impurity adduct grade, continuing to entrust HiSiaddi with overall customized formula coordination. The client also referred two Belgian high-end pharmaceutical R&D enterprises to source samples of the same optimized catalyst grade.
1. Industry Pain Point: Domestic catalyst manufacturers focus on mass production cost reduction with fixed long-standing formulas, producing solely to meet general national standard specifications. Lacking downstream coupling process application data from European and American pharmaceutical manufacturers, they cannot flexibly adjust product formulas to resolve production abnormalities at end-user lines. Restricted by pharmaceutical registration regulations, overseas mid-to-high-end pharmaceutical enterprises cannot arbitrarily modify production processes; minor defects in catalyst formulas trigger sharp drops in finished product yield across entire production lines, creating severe technical information disconnection between supply and demand sides.
2. Core Value of HiSiaddi: Drawing on dual technical reserves of precious metal catalyst synthesis and pharmaceutical coupling processes, we deliver a full-chain technical service covering fault tracing and diagnosis → refined product formula modification → matching on-site feeding process optimization → mass production quality control implementation. We break technical barriers between production manufacturers and end application clients, securing long-term stable cooperation with European high-end pharmaceutical enterprises through professional technical services.
For more formula optimization consulting services, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
